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preservation and avoids permanent colostomy. Aim of this work was to 
give an overview on up-to-date technical possibilities and clinical 
results of the brachytherapy boost treatment in anal canal cancer.  
Material and Methods: A literature review was performed and 
synchronized with personal experience on the field. Special focus was 
taken on image guided (image adapted) interstitial brachytherapy 
methods. Investigated imaging guidance possibilities include the use 
of 3D transrectal ultrasound, MRI- and CT imaging. Preplanning and 
real-time planning methods are discussed. The role of FDG  -PET in 
target definition as well the role of LDR, PDR and HDR brachytherapy 
methods were analyzed in relation to clinical results. Outcome and 
toxicity data were reviewed according to different dose levels and 
techniques. 
Results: Modern external beam technology (IMRT) improves the results 
of radiotherapy w/o chemotherapy. FDG-PET seems to be superior to 
CT in visualization of the primary tumor. Image fusion (PET/MRI /CT) 
can improve the results of a single imaging method; however, 3D 
transrectal ultrasound represents the most appropriate local imaging 
for target definition. Radiation dose is associated with local control in 
locally advanced anal cancer: higher dose and shorter overall 
treatment time (>54 Gy within 60 days) improve the results. Most of 
the studies report local control (LC) rates with anal function 
preservation at five years of >80% in small tumors and ~ 65-70% in 
T3/4 disease. Nodal stage is the most significant factor influencing 
overall survival (~66% at 5 years). PDR appears to be able reproducing 
the good continuous LDR treatment results. Image guided/adapted 
HDR brachytherapy boost complementary to IMRT w/o chemotherapy 
results in moderate decrease of late radiation proctitis data. Usually, 
brachytherapy boost reduce severe acute toxicity of high-dose IMRT 
and offer a low late toxicity rate (18% G3/G4). Controlled QoL 
investigations showed slightly better but not significant differences in 
toxicity of HDR boost compared to IMRT boost - in advantage of 
brachytherapy.  
Conclusions: Interstitial brachytherapy boost complementary to 
external beam treatment is an effective dose escalation method in 
function preservation therapy of anal canal cancers. Total dose level 
and total treatment time are important factors for the outcome. 
Modern, image guided and adapted brachytherapy technology 
compared to careful patient selection has the potential to reduce late 
toxicity and preserve function.  
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Introduction: After a golden age (1980-1990) with a lot of 
publications and presentations of Head and Neck (H&N) cancers and 
LDR manual brachytherapy this area has become an increasing silent 
area of brachytherapy (BT). 
This happened despite of the following:  
 Good historical data with high local control rate (LC) and 
preservation of function and anatomy.  
 New emerging technologies (PDR and HDR) with perfect 
radiation protection and improved patient care  
 Improved 3D CT-based dose planning with possibilities for dose 
optimization.  
Materials and Results: Since 1994 PDR BT has been routinely used in 
our hospital as a modern substitute for LDR in the treatment of H&N 
cancers. We present our experience in four different indication groups 
with examples: 
A) Mono brachytherapy for cancer of the Lip (PDR 60Gy for 6 days) 
where we found a 5- year LC of 95 %. In other T1-T2 Squamous or 
Basal cell Carcinomas in the H&N region treated by interstitial or 
surface applications we found a 90% LC rate. 
B) Boost brachytherapy (PDR 35 Gy for 3,5 days) of Base of Tongue 
(BOT) cancer (43% were T3-T4) we obtained 89% LC after 5 years. A 
lot of other areas for BT boost in H&N cancers are also of interest. 
C) Reirradiation of local recurrences. No systematic data available. 
High LC reported but with a significant risk of soft tissue necroses. 
 D) Adjuvant brachytherapy after marginal or non-radical surgical 
resection. No systematic data available. The combined procedure is 
feasible in our experience and should be further investigated in the 
future.  
 
Discussion and conclusions:  In our experience modern machine 
afterloading with PDR is at least as effective as classical LDR BT. 
Systematic data on HDR BT in H&N cancers is sparse but probably is 
similar in effect. 
Modern BT will improve patient care and dose planning. 
Long time follow up with high patient numbers is crucial to study 
these relatively rare tumour sites. International pooled data analyses 
organized by the ESTRO H&N working group are being planned. 
Theoretical education (an ESTRO course) and practical training (at 
several European training sites organized by ESTRO) in modern H&N 
cancer brachytherapy are essential for the future development of this 
area. 
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The ULICE project - Union for Light Ion Centers in Europe - started in 
2009 and it is now in its final phase. In the ULICE community a 
discussion on how to go ahead exploiting the major scientific results 
got from the project research activities is open. The most important 
output will be the creation of a European Hadron Therapy Research 
Board. This structure will be a multi-centres research organisation 
willing to go beyond ULICE. Taking advantage of the network of 
communication and research, both clinical and pre-clinical, 
constructed during the course of the project, it should be feasible to 
continue with exchange of experiences, enhance clinical and 
translational research between current, and future, European Hadron 
Therapy Centers, all of them being partners of the ULICE consortium. 
Mentioned multi-centre international setting can really urge radio-
oncology and hadron therapy in particular to raise a shared clinical 
evidence.   
The main tasks of the building up European Hadron Therapy Research 
Board will be 1) to guide the design, implementation, operation and 
continuous evaluation of a prospective multi-centre database for 
patients treated in a defined consortium of centres with carbon ions, 
protons, advanced photons; 2) to guide the design, performance and 
results of database orientated research; 3) to design, to decide and to 
follow up on multi-centre phase I, II, and III clinical studies performed 
in the carbon-ion centres alone or in combination with photon and/or 
proton facilities; 4) to link translational research from various areas of 
interest and research groups to ongoing and projected clinical trial 
and database orientated research. 
The activities of this European Hadron Therapy Research Board will be 
linked to all relevant clinical radiotherapy research organisations and 
networks on the international/ national/regional level in European 
member states and regions which focus on hadron and advanced 
photon radiotherapy research.  
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MEDRAPET (MEDical RAdiationProtection Education and Training, 
MEDRAPET) is a European Commission project aimed to improve the 
implementation of the Medical Directive’s provisions related to 
radiation protection education and training of medical professionals in 
the EU member states. The professional organizations involved include 
the European Society of Radiology (ESR) as a coordinator, the 
European Federation of Organizations for Medical Physics (EFOMP), 
the European Federation of Radiographer Societies(EFRS), the 
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European Society for Therapeutic Radiology and Oncology (ESTRO), 
the European Association of Nuclear Medicine (EANM) and the 
Cardiovascular and Interventional Radiological Society of Europe 
(CIRSE). The activities of MEDRAPET have focused on three main tasks 
i.e. a) the conduction of a survey onradiation protection education 
and training of medical professionals in the EUmember states, b) the 
organization of a European workshop and c) thedevelopment of a 
European Guidance document on radiation protection educationand 
training of medical professionals.   
A European Union study was performed to obtain a view on the status 
and legal and practical arrangements in the European Member States 
regarding radiation protection education and training of medical 
professionals. A questionnaire with specific sections for radiation 
protection authorities, national professional societies and educational 
institutions was developed. For the radiation protection authorities 
section, there were 28 respondents (57.1% response rate). The 
response rate for professional societies was 25.3% (509 contacts - 129 
answers) and for educational institutions 19.8% (465 contacts – 92 
answers). Results of this survey show that there is a need for 
implementation of the medical exposure directive’s requirements on 
radiation protection education and training of medical professionals in 
many states of the European Union. Also, interventional cardiologists, 
vascular surgeons and other interventionalists have a need for 
dedicated training in radiation protection for fluoroscopically-guided 
interventional procedures. 
The results of the MEDRAPET survey were discussed during the 
MEDRAPET workshop organized in Athens, Greece from 21 to 23 of 
April, 2012. A wide audience of professionals involved in medical 
radiation protection attended the workshop (one hundred and eight 
participants from 29 different countries). Representatives of 
international organizations, professional societies, regulatory 
organizations and university students examined opportunities, 
difficulties and future trends in medical radiation protection 
education and training. Input was obtained for the drafting of the 
guidance document. The guidance document provides guidelines on 
radiation protection education and training of medical professionals in 
the European Union. The main part of the guidance document is 
focused on learning outcomes for each medical profession working 
with ionizing radiation defined interms of knowledge, skills and 
competence (KSC) in accordance with the European Qualifications 
Framework and the European Guidelines for lifelong learning.  
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As the final outcome of the MEDRAPET project, the guidance 
document shall give specific learning outcomes for each professional 
group, reflecting its need for education and training in radiation 
protection. The section on radiologists concentrates on those aspects 
where radiologists are most influential, and learning outcomes of 
education and training in radiology are presented in KSC table format, 
according to the systematic structure used for  the presentations of all 
medical professions. The contents have been coordinated with the 
Education Committee of the European Society of Radiology and will be 
reflected in the revised training charter for radiologists.  
CT alone is responsible for at least 50% of the medical exposure to the 
population in most European countries, and the risk is mostly 
stochastic. This contribution is the result of both a high number of 
examinations and a relatively elevated individual patient dose. 
Radiologists - in cooperation with the referring clinician - are 
responsible for justification; choosing the best imaging method for 
each individual medical problem, thus, has a top priority in the 
learning objectives. In addition, in CT optimisation - depending on 
the specific application - can reduce individual exposure by around 
50% to 90%. This has become possible through technical advances 
(such as automatic exposure control and iterative image 
reconstruction) but requires adequate knowledge of the different 
tools and protocol adaptation to the specific body habitus, most 
important in children and obese adults. 
Similar to CT, optimisation and justification are important for 
radiographic and fluoroscopic examinations although the 
contribution to the exposure of the population is smaller. In 
fluoroscopy, two additional aspects have to be covered by the 
learning objectives: deterministic effects (mainly to the skin) and 
occupational exposure of the personnel are therefore included in the 
education. 
Interventional radiology is different from general radiology in that 
the vast majority of activities have a therapeutic component and are 
often applied to elderly, critically ill patients; the stochastic risk is 
limited here but the deterministic risk increases. This turns the 
priority of education towards optimisation. Interventional radiologists, 
consecutively, undergo the usual education and training of radiologists 
before they deepen their knowledge (K), skills (S) and competences 
(C) in these aspects during the period of subspecialisation. 
Radiation protection is life-long learning and therefore an integral 
part of continuous professional development. 
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The  ACCIRAD Project is run by the Consortium of the following 
partners Radiation and Nuclear Safety Authority, (Helsinki), Public 
Research Centre Henri Tudor (Luxemburg),  Nuclear Safety Authority 
(Paris); ESTRO; Fundacion Investigacion Biomedica Hospital Clinico San 
Carlos (Madrid) and coordinated by  the Greater Poland Cancer Centre 
from Poznan.  A Panel of 11 Scientific Experts was set up for the 
assessment of the work plans and the results achieved and for the 
support of specified tasks. 
Aim: The main objective is to perform an EU-wide study on the 
implementation of the MED requirements aimed at the reduction of 
the probability and the magnitude of accidents in radiotherapy and to 
develop guidelines on a risk analysis of accidental an unintended 
exposures in external beam radiotherapy. 
Methodology: There are 6 work packages: Management and 
coordination; Questionnaires on MED implementation; Risk analysis of 
accidental and unintended exposures; Classification, reporting, and 
registration of events; European Guidelines; European Workshop. The 
project works are prepared by partners and discussed during six 
meetings and three video conferences. 
The lead contractor is responsible for the management and 
coordination of the project and has ensured the organisation and 
resources needed to fulfill the objectives of the contract. The 
questionnaire was sent out to establish the overall status and the legal 
and practical arrangements in EU Member States. The questionnaire 
was carried out in two steps: general and detailed. The methods or 
risk analyses are being reviewed, partly by an expert knowledge of the 
consortium, partly based on the results of the questionnaire. The 
European Guidelines will be a document on a risk analysis of 
accidental and unintended exposures in external beam radiotherapy 
and will provide comprehensive description of best practices to 
conduct a study of risk of accidental or unintended exposures. The 
proactive methods to identify vulnerable aspects of the radiotherapy 
treatment, using risk matrix or probabilistic safety assessment will 
also be presented in detail. The European Guidelines will be discussed 
during the European Workshop where the feedback from the invited 
expert organisations is awaited.  
Conclusions: More than half of the EU Countries have already 
implemented a requirement for risk analysis in radiotherapy, and 
classification recording, and reporting of adverse events and near 
misses in their legal systems. However, the requirement for legal 
framework for risk analysis, classification of events, recording and 
reporting systems has not been addressed in many EU countries, and 
thus, the practical implementation of the systems in many countries is 
still incomplete. 
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